Actualités - Nuvaira

Nuvaira Announces Published Two-Year Results in COPD Patients treated with Targeted Lung Denervation

novembre 23, 2020/dans newsroom @fr, Non classifié(e), Publications /par Amy Wolter

AIRFLOW-2 two-year data confirm sustained reduction of severe COPD exacerbation risk vs. a control group. MINNEAPOLIS, Nov. 23, 2020 /PRNewswire/ — Nuvaira, a developer of novel therapeutic strategies to treat obstructive lung diseases, announced today publication of two-year follow-up data from its randomized, sham-controlled, double-blinded trial (AIRFLOW-2) that confirms long-term safety and durable effect of Targeted Lung Denervation […]

Nuvaira Announces FDA Breakthrough Designation for AIRFLOW-3 Pivotal Trial Device

juin 9, 2020/dans newsroom @fr /par Amy Wolter

Inspire Medical Systems CEO Tim Herbert has joined Nuvaira Board of Directors MINNEAPOLIS, June 8, 2020 – Nuvaira, a developer of novel therapeutic strategies to treat obstructive lung diseases, has announced that its Nuvaira® Lung Denervation System has been designated as a Breakthrough Device by the U.S. Food and Drug Administration (FDA). This program creates […]

First patients successfully treated in the Nuvaira AIRFLOW-3 COPD pivotal trial

juillet 9, 2019/dans newsroom @fr, Non classifié(e) /par eric iverson

A first for Temple University Hospital and U.S. Patients MINNEAPOLIS, June 10, 2019 – Nuvaira, developer of novel therapeutic strategies to treat obstructive lung diseases, announced the first treatments in the AIRFLOW-3 pivotal trial, the first interventional COPD trial to target reduction in COPD exacerbations as a primary endpoint. Two U.S. patients were successfully treated […]

Nuvaira Receives French Innovation Funding for AIRFLOW-3 Pivotal Trial

mai 7, 2019/dans newsroom @fr, Non classifié(e) /par Amy Wolter

Novel program provides reimbursement for TLD therapy in France MINNEAPOLIS, April 28, 2019 – Nuvaira, developer of novel therapeutic strategies to treat obstructive lung diseases, has received acceptance from the Haute Autorité de Santé (HAS, the French health technology assessment agency) into its Forfait Innovation program. The program is designed to fast-track novel medical devices […]